Celldex Therapeutics (CLDX) Projected to Post Earnings on Thursday

Key Points

• Q1 2026 earnings are scheduled to be released before the market opens on May 14, with analysts expecting a loss of ($1.1322) per share and revenue of $0.795 million; an investor call is listed for May 11 at 4:00 PM ET.
• Celldex missed the prior quarter, reporting ($1.22) EPS vs. a ($1.00) consensus and $0.12M revenue vs. $1.53M, and analysts project roughly -$5 EPS for both the current and next fiscal years.
• The stock trades near its 52-week high (opened $34.39, high $35.79) with a $2.7B market cap; consensus sentiment is a Moderate Buy with an average target of $46.36, though analyst targets range widely (e.g., Barclays $45, Stifel $68).

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) is expected to be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Celldex Therapeutics to post earnings of ($1.1322) per share and revenue of $0.7950 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. On average, analysts expect Celldex Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $34.39 on Thursday. Celldex Therapeutics has a fifty-two week low of $17.85 and a fifty-two week high of $35.79. The stock's 50-day moving average is $31.52 and its two-hundred day moving average is $27.82. The firm has a market cap of $2.70 billion, a P/E ratio of -8.84 and a beta of 0.98.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Panagora Asset Management Inc. lifted its position in Celldex Therapeutics by 7.5% in the 4th quarter. Panagora Asset Management Inc. now owns 21,856 shares of the biopharmaceutical company's stock valued at $594,000 after acquiring an additional 1,522 shares in the last quarter. Marex Group plc bought a new stake in Celldex Therapeutics in the 4th quarter valued at $223,000. Brevan Howard Capital Management LP bought a new stake in Celldex Therapeutics in the 3rd quarter valued at $372,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Celldex Therapeutics by 19.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,800 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 3,740 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Celldex Therapeutics by 218.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,362 shares of the biopharmaceutical company's stock valued at $190,000 after acquiring an additional 5,047 shares in the last quarter.

Analysts Set New Price Targets

CLDX has been the subject of a number of recent analyst reports. Barclays upgraded shares of Celldex Therapeutics from an "underweight" rating to an "overweight" rating and upped their price target for the company from $24.00 to $45.00 in a report on Monday, April 20th. Wolfe Research raised shares of Celldex Therapeutics from a "peer perform" rating to an "outperform" rating and set a $44.00 price objective for the company in a report on Monday, March 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Celldex Therapeutics in a report on Monday, April 20th. Stifel Nicolaus reissued a "buy" rating and issued a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, The Goldman Sachs Group raised their price target on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $46.36.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.